Please wait
​
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
​
FORM 6-K
​
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2024
Commission File Number: 001-40850
​
Exscientia plc
(Translation of registrant’s name into English)​
​
The Schrödinger Building
Oxford Science Park
Oxford OX4 4GE
United Kingdom
(Address of principal executive office)​
​
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F
☐ Form 40-F
​
​
​
​
 
EXHIBIT INDEX
​
Exhibit
Number
​ ​
Description of Exhibit
​
​
99.1
​ ​ Definitive Joint Proxy Statement of Exscientia plc and Recursion Pharmaceuticals, Inc., dated October 10, 2024, in connection with the shareholder meetings of Exscientia plc and the special meeting of stockholders of Recursion Pharmaceuticals, Inc., each related to the transactions contemplated by the Transaction Agreement by and between Exscientia plc and Recursion Pharmaceuticals, Inc. dated as of August 8, 2024 ​
* * *
 
​
 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​ ​ ​ ​ EXSCIENTIA PLC ​
​ ​ ​ ​ By: ​ ​
/s/ Ben Taylor
​
Name: Ben Taylor
Title:  Chief Financial Officer
​
​ Date: ​ ​ ​ ​ ​ ​ ​
​ October 10, 2024 ​ ​ ​ ​ ​ ​ ​